We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Human Genome Sciences Appoints Tuan Ha-Ngoc to its Board of Directors

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Human Genome Sciences Appoints Tuan Ha-Ngoc to its Board of Directors "

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Human Genome Sciences, Inc. has announced that Tuan Ha-Ngoc, President and Chief Executive Officer of AVEO Pharmaceuticals, Inc., has been appointed to the company's Board of Directors.

Mr. Ha-Ngoc has served as President and CEO since AVEO's inception in 2002 (formerly known as GenPath Pharmaceuticals, Inc.). From 1999 to 2002, he was co-founder, President and CEO of deNovis, Inc.

From 1998 to 1999, Mr. Ha-Ngoc was Corporate Vice President of Strategic Development for Wyeth (formerly known as American Home Products Corporation), following Wyeth's acquisition of Genetics Institute, where Mr. Ha-Ngoc served as Executive Vice President with responsibility for Corporate Development, Commercial Operations, European and Japanese Operations.

Prior to joining Genetics Institute in 1984, Mr. Ha-Ngoc held various marketing and business positions at Baxter Healthcare, Inc.

He received his MBA degree from INSEAD and his Master's degree in pharmacy from the University of Paris, France.

Mr. Ha-Ngoc serves on the Board of Directors of Arqule, Inc., and on the Boards of a number of academic and nonprofit organizations, including the Harvard School of Dental Medicine, the Tufts School of Medicine, the Belmont Hill School, the Boston Philharmonic Orchestra, and the International Institute of Boston.

H. Thomas Watkins, Chief Executive Officer of Human Genome Sciences, said, "Tuan Ha-Ngoc brings to Human Genome Sciences more than 30 years of experience in the development and commercialization of biopharmaceutical and healthcare products and organizations."

"We are honored to have him join our Board of Directors, and we look forward to benefiting from his knowledge and insight."

"He will be a strong addition to our Board as we continue to advance our products through late-stage development and toward commercialization."

Human Genome Sciences also announced  that Kathryn (Kate) Falberg, retired Chief Financial Officer of Amgen and an entrepreneur and corporate director, has resigned from the company's Board of Directors to devote more time to her other business and personal interests.

Mr. Watkins said, "We thank Kate Falberg for her service and contributions to Human Genome Sciences during her term as a Director, and we wish her well."